1Ishii N, Watanabe H, Isrisawa C, et al. Intracavemous injection of PGE1 For the treatment of the treatment of erectile in potence[J] .Jurol, 1989,141:323.
1NIH Consensus Conference.NIH Consensus Development Panel on Confererce. Impotence. JAMA 1993:270-283.
2Campos de Carvalho AC, Roy C, Moreno AP, et al.Gap junction formed of connexin 43 are found between smooth muscle cells of human corpus cavernosum. Urology 1993;149(6): 1568-1575.
3Heaton JP, Varrin SJ,Morales A. The characterizaion of a bio-assay of erectile function in a rat model. Urology 1991; 145(5): 1099-1102.
4Akingba AG, Bumett AL. Endothelial nitric oxide synthase protein expression, localization, and activity in the penis of the alloxan-induced diabetic rat. Mol Urology 2001; 5(4): 189-197.
5Podlasek CA, Zelner DJ, Bervig TR, et al. Characterization and localization of nitric oxide synthase isoforms in the BB/WOR diabetic rat. Urol 2001; 166(2): 746-755.
6Savoca G, Silvestre G, Belgrano E. Intracavernosal injection therapy and surgical therapy in diabetic patients with erectile dysfunction. Diabetes Nutr Metab 2002; 15(1): 53-57.
7DCCT Reserch Group. The effect of intensive treatment of diabetes in the development and progression of long- term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-986.
8UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
